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The discovery of the new antibiotic teixobactin has been 
timely in the race for unearthing novel antibiotics wherein 
the emergence of drug resistance bacteria poses a serious 
threat worldwide. Herein, we present the total syntheses and 
biological activities of two teixobactin analogues. This 
approach is simple, efficient and has several advantages: it 
uses commercially available building blocks (except AllocHN-
D-Thr-OH), has a single purification step and a good recovery 
(22%). By using this approach we have synthesised two 
teixobactin analogues and established that the D-amino acids 
are critical for the antimicrobial activity of these analogues. 
With continuing high expectations from teixobactin, this 
work can be regarded as a stepping stone towards an in 
depth study of teixobactin, its analogues and the quest for 
synthesising similar molecules.  
 
The decreased potency of drugs such as penicillin,
1
 
vancomycin
2
 and oxacillin
3
 due to their excessive use is a 
consequence of the emergence of drug resistant bacteria. It 
has been predicted that Antimicrobial Resistance (AMR) will 
have disastrous consequences and it is estimated that by 2050 
an additional 10 million people yearly could succumb to drug 
resistant infections.
4
 The recently published article in Nature
5
 
describing the discovery of teixobactin has provided a much 
needed breakthrough in the challenging field of antibiotic 
peptides. The bacteria against which it is effective have, thus 
far, not shown any detectable resistance to teixobactin. 
Moreover, given the multiple mechanisms of attack by 
teixobactin described by Süssmuth
6
 resistance is unlikely in the 
near future. Unfortunately, although teixobactin provides 
some much needed answers, the problem is far from over. 
Organic chemists have worked round the clock to synthesise 
novel antibiotics and although progress has been steady, 
bacteria have time and again confounded even the best in this 
field.
7
 This is where the multichannel device, iChip,
8
 has made 
a considerable contribution enabling the identification of 
molecules like teixobactin, some of which could be active 
against drug resistant bacteria. However, the iChip device has 
its limitations. The probability of finding an antibiotic is 
extremely low (10
-7
 percent) and even with high-throughput 
screening, which takes considerable time and resources, there 
is no guarantee when will be the discovery of the next drug 
like teixobactin. Undeniably, breakthroughs via organic 
synthesis have to be made to keep the drug resistance 
problem under check. The time for this is indeed now and 
teixobactin is a good starting point. This study is aimed at 
doing so and provides a general approach through which, not 
only teixobactin, but also other analogues can be synthesised. 
The total synthesis of teixobactin will give access to analogues 
which nature cannot provide us with and therefore an organic 
synthesis approach to the bigger problem at hand should not 
be prematurely discarded. It is to be noted that during the 
preparation of this manuscript a report from the Albericio 
group appeared describing the synthesis of Teixobactin 
analogue 1 obtained in a 6% yield. Moreover, the role of the D-
amino acids have not been proven.
9
 Our work presents 
efficient syntheses of both the D and L versions of the 
analogues of teixobactin (22% yield for 1) and their role in 
antimicrobial activity. 
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Figure 1a: (left) Structure of teixobactin. Figure 1b: (right) Structure of the teixobactin analogue 1 showing the bonds to be cleaved for the synthesis routes A (in blue) 
and B (in red) and the structural differences (in green) 
 
 Since teixobactin has been fully characterised by NMR and 
LC-MS, the structural complexity of teixobactin can be 
described as moderate to difficult. It has also been described 
as an unusual depsipeptide due to the presence of the non-
natural amino acids L-allo-enduracididine and N-
methylphenylalanine along with four D-amino acids (Fig. 1). 
Despite not possessing a lipid tail, the commercial 
unavailability of the enduracididine amino acid makes the total 
synthesis of the molecule more time consuming than 
expected.
10
 The commercially available natural amino acid 
arginine (a linear guanidine) is the closest structural match 
suitable for the replacement of the L-allo-enduracididine (a 
cyclic guanidine) as can be seen in figure 1 (green). In this 
work, arginine was selected as a replacement of 
enduracididine for synthesise of teixobactin analogue 1. A first 
approach towards tackling this molecule was to synthesise the 
complete peptide on solid phase and cyclise post-cleavage 
from the resin via an ester bond (SI figure S1). This route has 
been used with success for the synthesis of the analogues of 
callipeltin B.
11
  
 Following this strategy, a fully protected linear peptide was 
synthesised and cleaved from the resin without cleaving the 
protecting groups. However, the synthesis failed at the 
esterification step. Several conditions have been tested for the 
esterification as described in Table 1 (SI). Unfortunately, none 
of them yielded the esterified product.  This could be due to 
the steric bulk of protecting groups on the amino acids. This 
led to the conclusion that a direct and linear route is not the 
way to cyclisation. Therefore a new second synthetic route had 
been devised which involves cyclisation via amide bond 
formation (figure 1b). For the total synthesis of analogue 1, an 
optimised pathway for the synthesis of the core ring structure 
(2) of teixobactin was required. Therefore, the initial efforts 
were focussed on obtaining this key fragment (figure 2).  
 For optimisation of the synthesis, we chose Wang resin. 
Fmoc-Ala-OH was loaded onto this resin via ester bond 
formation. The unreacted resin was capped using 10% acetic 
anhydride/diisopropylethylamine (Ac2O/DIPEA) followed by (a) 
the attachment of Fmoc-D-Thr(Trt)-OH via amide bond 
formation and subsequent (b) Fmoc removal. The orthogonal 
Alloc protecting group was installed on the amine (c) followed 
by (d) trityl group removal by 1:5:96 TFA:TIS:DCM and 
proceeded with (e) the challenging esterification reaction 
between Ile and Thr. It is to be noted that excess Ile and base 
were required to drive the reaction to completion.
12
 This was 
succeeded by (f) amide bond formation using Arg and 
subsequent (g) cleavage from the resin using 95:2.5:2.5 
TFA:TIS:H2O. The final step was (h) the amide bond formation 
between Arg and Ala which proceeds smoothly yielding the 
desired cyclized fragment. This approach was then slightly 
modified and used for the total synthesis of the teixobactin 
analogue 1 as described in figure 3. 
The approach used in this work involves synthesising the 
peptide completely on solid phase and only a single 
purification was required after the final cleavage. The 
synthesis of building block AllocHN-D-Thr-OH (modified from 
reference 13) was also reported for first time and which can be 
directly coupled to the resin without protecting the amino acid 
side chain. 2-chlorotritylchloride resin was chosen instead of 
Wang resin as the peptide could be cleaved off from the resin 
without removing the side chain protecting groups of the 
attached amino acids.
14
 
Figure 2: Synthesis scheme for the core teixobactin fragment 2 starting from 
Wang resin:   a. 10 eq. Fmoc-Ala-OH, 10 eq. DIC, 1 eq. DMAP followed by 10% 
Ac2O/DIPEA in DMF.   b. 2.5 eq. Fmoc-D-Thr(Trt)-OH, 2.5 HATU/5 eq. DIPEA, 3h 
DMF followed by 20% piperidine in DMF.   c. 4 eq. Allyl Chloroformate/8 eq. 
DIPEA in DCM, 1h.  d. 1:5:96 TFA:TIS:DCM. 3 x 15 min.   e. 10 eq. Fmoc-Ile-OH, 10 
eq. DIC, 10 mol% DMAP in DCM, 2h followed by 10% Ac2O/DIPEA in DMF, 
followed by 20% piperidine in DMF.   f. 4 eq. Fmoc-Arg(Pbf)-OH, 4 eq. HATU/8 
eq. DIPEA in DMF, 1h followed by 20% piperidine in DMF.   g. TFA:TIS:H2O = 
95:2.5.2.5, 1h.   h. 1 eq. HATU/10 eq. DIPEA in DMF, 1h, monitored on HPLC. 
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Figure 3: Total synthesis of analogue 1 starting from 2-Chlorotritylchloride resin: a. 4 eq. Fmoc-Ala-OH/8 eq. DIPEA in DCM, 3h.   b. 20% piperidine in DMF followed by 
3 eq. AllocHN-D-Thr-OH, 3 eq. HATU/6 eq. DIPEA.   c. 10 eq. Fmoc-Ile-OH, 10 eq. DIC, 5 mol% DMAP in DCM, 2h followed by capping with Ac2O/DIPEA 10% in DMF, 
20% piperidine in DMF   d. 4 eq. Fmoc-Arg(Pbf)-OH, 4 eq. HATU/8 eq. DIPEA in DMF, 1h followed by 20% piperidine in DMF   e. 10 eq. Trt-Cl, 15% Et3N in DCM, 1h.  f. 
[Pd(PPh3)4]
0
 (0.2 eq.) + 24 eq. PhSiH3 in DCM, 2 x 1 h.   g. Fmoc/Boc-AA(PG)-OH (AA = amino acid, PG = protecting group), HATU/DIPEA followed by 20% piperidine in 
DMF.   h. TFA:TIS:DCM = 2:5:93, 2h.  i. 1 eq. HATU/10 eq. DIPEA in DMF, 1h, monitored on HPLC.   j.  TFA:TIS:H 2O = 95:2.5:2.5, 1h. 
(a) The first amino acid loaded on the resin in this case is 
Fmoc-Ala-OH followed by (b) an amide bond coupling with 
Alloc-D-Thr-OH. (c) Fmoc-Ile-OH is then coupled at this stage 
via an ester bond to the free –OH side chain of threonine. 
Next, (d) arginine was coupled via an amide bond, the Fmoc 
protecting group is removed and (e) the N-terminus is 
protected via a trityl protecting group
15
 (combining cleavage 
and deprotection in a single step) to facilitate the cleavage and 
cyclisation as described in reactions h and i. (f) The alloc group 
protecting the N-terminus of the threonine is then removed
16
 
and (g) the peptide chain is built via standard Solid Phase 
Peptide Synthesis (SPPS). Partial cleavage was performed using 
2:5:93 TFA:TIS:DCM followed by cyclization using 1-
[Bis(dimethylamino) methylene]-1H-1,2,3-triazolo[4,5-
b]pyridinium 3-oxid hexafluorophosphate (HATU) as a coupling 
reagent and DIPEA as a base in DMF for 1 hr. The protecting 
groups are then cleaved off using 95:2.5:2.5 TFA:TIS:H2O 
yielding the desired peptide (22% recovery, refer SI, S10). After 
successful synthesis of analogue 1, the general applicability of 
this approach was tested for the synthesis of analogue 3 (figure 
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4). In analogue 3, the three D-amino acids residues (Phe, Gln 
and Ile) were replaced by L-amino acid residues. The synthesis 
of analogue 3 was also worked efficiently (17% recovery, refer 
SI, S10). 
 
Figure 4: Structure of analogue 3 
 The detailed characterisation of 1 and 3 were performed 
using LC-MS and NMR. The NMR spectra of product 1 (refer SI, 
page S15) was shown to be identical as reported previously
5,9
. 
The NOEs of 1 were characteristic of a random coil, however, 
the NOEs of 3 suggested a considerable degree of structure.  
 The analogues 1 and 3 were evaluated for their 
antibacterial activity. MIC results showed a trend similar to 
teixobactin for analogue 1 against both Gram-positive and 
Gram-negative bacteria. Analogue 3 was not active against 
Gram-negative bacteria. Moreover, analogue 1 was 64 times 
more effective than analogue 3 (table 1) against Gram-positive 
bacteria. This difference in antibacterial activity has 
established that the three D-amino acids residues of 1 are 
critical for the antibacterial activity. 
Entry Organism 1  3  Teixobactin 
1 
S. aureus ATCC 
25923 2 128 0.25
* 
2 
E. coli ATCC 
25922 64 GAW
‡ 25 
Table 1. MIC (µg/ml) for 1 and 3 and Teixobactin (MICs from ref. 5, 0.25* were from a 
different strain of S. aureus). ‡Growth in all wells 
 In conclusion, this work reports efficient total syntheses of 
two teixobactin analogues (22% yield of teixobactin analogue 
1). Analogue 1 is identical to teixobactin in all aspects with the 
exception of the L-allo-enduracididine amino acid.  The 
methodology described here is not specific to only one 
molecule, but it can also be used as a general strategy for 
synthesis of other analogues of teixobactin. The role of three 
D-amino acids had also been established. The three D-amino 
acids present in the teixobactin analogue 1 but absent in 
analogue 3 are critical for antibacterial activity.  This work also 
reports the synthesis of new AllocHN-D-Thr-OH building block 
and has incorporated it as such in the syntheses of teixobactin 
analogues. We believe that this work to be pivotal for the 
synthesis of teixobactin and its analogues and therefore will 
helpful be to address the current challenges of antimicrobial 
resistance.  
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